Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
casdatifan + pumitamig
- Development stage
- Phase 2
- Lead developer
- Arcus Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Casdatifan plus pumitamig is an investigational combination regimen being evaluated for the treatment of advanced renal cell carcinoma (RCC). Casdatifan (AB521) is an oral, once-daily small-molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α), developed by Arcus Biosciences. Pumitamig (BNT327/BMS-986545/PM8002) is an investigational bispecific antibody jointly developed by BioNTech and Bristol Myers Squibb that targets programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A). The combination is being evaluated in the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical trial (NCT07293351) as a potential tyrosine kinase inhibitor (TKI)-sparing first-line treatment option for patients with advanced clear cell RCC.
- Other names
- AB-521 + BNT-327AB-521 + BMS-986545AB-521 + PM8002AB521 + BNT327AB521 + BMS-986545AB521 + PM8002casdatifan plus pumitamigpumitamig + casdatifanpumitamig plus casdatifan
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on casdatifan + pumitamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on casdatifan + pumitamig.